Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

Aldeyra Therapeutics和其他2只低於5美元的股票內部人士正在買入

Benzinga · 04/04 18:23

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Aldeyra Therapeutics

The Trade: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 10% owner Joseph Edelman acquired a total of 504,272 shares an average price of $3.84. To acquire these shares, it cost around $1.93 million.
What's Happening: On April 3, Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.
What Aldeyra Therapeutics Does: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.

Retractable Technologies

The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 8,292 shares at at an average price of $1.15. To acquire these shares, it cost around $9,499.
What's Happening: On March 29, Retractable Technologies reported results for 2023.
What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.

Alzamend Neuro

The Trade: Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C Ault III acquired a total of 334 shares at an average price of $0.91. The insider spent around $304 to buy those shares.
What's Happening: On Dec. 11, 2023, Alzamend Neuro received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD).
What Alzamend Neuro Does: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's.

Don't forget to check out our premarket coverage here

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週三收盤下跌約0.1％。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的細價股內幕交易。欲了解更多，請查看 本辛加的內幕交易 平台。

Aldeyra Therapeutics

Aldeyra Therapeutics

The Trade: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 10% owner Joseph Edelman acquired a total of 504,272 shares an average price of $3.84. To acquire these shares, it cost around $1.93 million.
What's Happening: On April 3, Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.
What Aldeyra Therapeutics Does: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.

交易：Aldeyra Therapeutics, Inc.（納斯達克股票代碼：ALDX）10% 的所有者約瑟夫·愛德曼 共收購了504,272股股票 平均價格爲3.84美元。收購這些股票的成本約爲193萬美元。
發生了什麼：4月3日，奧本海默將該股從表現上調至跑贏大盤，並宣佈了10美元的目標股價。
Aldeyra Therapeutics的所作所爲：Aldeyra Therapeutics Inc是一家生物技術公司，致力於開發和商業化下一代藥物，以改善免疫介導疾病患者的生活。

Retractable Technologies

可伸縮技術

The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 8,292 shares at at an average price of $1.15. To acquire these shares, it cost around $9,499.
What's Happening: On March 29, Retractable Technologies reported results for 2023.
What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.

交易：Tractable Technologies, Inc.（紐約證券交易所代碼：RVP）總裁兼首席執行官 Thomas J Shaw 共收購了8,292股股票 平均價格爲1.15美元。收購這些股票的成本約爲9,499美元。
發生了什麼：3月29日，Retractable Technologies公佈了2023年的業績。
Tractable Technologies的作用：Tractable Technologies Inc爲醫療保健行業設計、開發、製造和銷售安全注射器和其他安全醫療產品。

Alzamend Neuro

Alzamend Neuro

The Trade: Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C Ault III acquired a total of 334 shares at an average price of $0.91. The insider spent around $304 to buy those shares.
What's Happening: On Dec. 11, 2023, Alzamend Neuro received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD).
What Alzamend Neuro Does: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's.

交易：Alzamend Neuro, Inc.（納斯達克股票代碼：ALZN）董事 Milton C Ault III 共收購了 334 股股票 平均價格爲0.91美元。知情人士花了大約304美元購買了這些股票。
發生了什麼：2023年12月11日，Alzamend Neuro收到了美國食品藥品管理局的 “研究可能繼續” 的信，要求啓動研究 AL001-PTSD01，這是一項針對創傷後應激障礙（PTSD）AL001 的2A期研究。
Alzamend Neuro做什麼：Alzamend Neuro Inc是一家處於早期臨床階段的生物製藥公司。它專注於開發用於治療神經退行性疾病和精神疾病（包括阿爾茨海默氏症）的新產品。

Don't forget to check out our premarket coverage here

別忘了在這裏查看我們的上市前報道

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。